Skip to content
Review Open access

Herb-Drug Interaction Safety: Clinical Implications, Molecular Mechanisms, and the Future of Integrated Medicine

Oct 2026 · International Journal of Drug Delivery Technology · 0 citations · 39 references

Abstract

Background: The concurrent use of herbal medicines and conventional pharmaceuticals has become a global health phenomenon, driven by a cultural shift toward holistic wellness and the pervasive misconception that "natural" products are inherently devoid of risk. This integration creates a complex pharmacological landscape where bioactive phytochemicals can significantly alter the therapeutic efficacy and safety profiles of prescription drugs. Objectives: This review aims to delineate the mechanistic underpinnings of Herb-Drug Interactions (HDIs), evaluate the clinical implications for high-risk patient populations, and assess current methodological advancements in risk prediction and surveillance. Methods: A multi-tiered framework is explored, encompassing pharmacokinetic (ADME) modulation— specifically involving Cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp) transporters—and pharmacodynamic pathways of synergy and antagonism. The role of in silico modeling, Artificial Intelligence (AI), and "herbovigilance" systems is evaluated as a modern strategy for mitigating iatrogenic harm. Results: Evidence suggests that HDIs pose the greatest threat to patients on Narrow Therapeutic Index (NTI) medications, such as anticoagulants and immunosuppressants. Pharmacokinetic induction, exemplified by St. John’s Wort ( Hypericum perforatum ), can lead to sub-therapeutic plasma levels and therapeutic failure, while irreversible inhibition, such as the furanocoumarin effect in grapefruit, may precipitate systemic toxicity. Furthermore, host-specific factors like age-related physiological decline and the extreme phytochemical variability of non-standardized herbal products exacerbate these risks. Conclusion: HDIs represent a paramount safety challenge in contemporary integrated medicine. To ensure patient safety, a paradigm shift is required that reclassifies herbal products as active pharmacological agents. This necessitates rigorous standardized labeling, mandatory clinical screening protocols, and the deployment of AI-driven predictive tools to bridge the existing "communication chasm" between patients and healthcare providers.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.